A COMPLEMENTARY AND EXPERIENCED TEAM
Gilles AVENARD
MD., Entrepreneur ; Strategy Consultant ; Board member or advisor for several biotech companies ; co-founder and CEO of BioAlliance Pharma SA (BIO-NYSE EURONEXT) until 2010. Gilles Avenard was involved in the development of several innovative medicines until their registration in Europe and the USA. Before that, he was Projects Director for Hoechst Marion Roussel (Sanofi) and Medical Director of Bio-Transfusion (LFB).
Olivier FAVRE-BULLE
Founder of 3Biotech, specialized in Pharmaceutical Development of Large and Small molecules. Site manager and European Head of Drug Development for Covance, Olivier also was head of NNE Pharmaplan France, a subsidiary of Novo Nordisk. He started at Rhône-Poulenc as Project Manager in Biological Drugs development. Chemical Engineer by training with a Ph.D in Bioengineering.
Philippe BILLIALD
Pharm. D. and PhD. in Biochemistry, Professor at Paris-Sud University ; Antibody Scientific Consultant and President of the Strategic Comity. Expert in the field of therapeutic and diagnostic antibody engineering, Philippe Billiald is the author of two patents and close to 40 papers in peer-reviewed scientific journals, books and scientific magazines.
Martine JANDROT-PERRUS
MD. and PhD. in Biochemistry, Research Director (DR1) at Inserm (UMR_S1148 Inserm Paris-Diderot University) ; Thrombosis Scientific Consultant. Internationally recognized expert of thrombosis and entitled with an Hospital Research contract in translational research with the AP-HP ; Martine Jandrot-Perrus is the author of 102 papers in international scientific journals and of 4 patents.
Christian GACHET
MD. and PhD. in Pharmacology, Research Director (DR1) at Inserm (UMR_S949 Inserm, EFS, Strasbourg university). Christian GACHET is an international expert in the field of thrombosis and antiplatelet drugs. He is the author of 189 papers in international scientific journals and of 3 patents.
Kristell Lebozec
Master of Biotechnology Engineering with a focus on R&D and Health. K. Lebozec has a 2 years experience in academic laboratories (Institut Gustave Roussy and Centre de Recherche des Cordeliers) and in the industry (DNA Therapeutics and I-Stem). She is in charge of selecting ACT017 expression system, designing analytical methods and of the functional characterization of products.
More details about the team which started the project on their research group websites :
